Clinical Trials Logo

Clinical Trial Summary

This is a randomised, double-blind, positive drug parallel controlled clinical trial in China. In the trial, it is planned to enroll 88 subjects, randomized to two treatment groups in a ratio of 1:1 to receive the test drug and the positive control.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04135898
Study type Interventional
Source Shanghai Institute Of Biological Products
Contact
Status Completed
Phase Phase 1
Start date October 23, 2019
Completion date March 16, 2020

See also
  Status Clinical Trial Phase
Completed NCT02395926 - To Evaluate Safety and the Pharmacokinetic Characteristics After Oral Administration of HT-003 Compared With Choline Alfoscerate Capsule in Healthy Adult Male Volunteers Phase 1
Recruiting NCT05849311 - Phase I Trial of Envafolimab for Healthy Male Subjects Phase 1
Active, not recruiting NCT06105255 - A Study to Evaluate the Effects of D-1553 on PK of Midazolam, Caffeine, Rosuvastatin, Furosemide, Digoxin, and Itraconazole or Omeprazole on PK of D-1553 Phase 1
Completed NCT01651234 - A Study to Assess Safety, Tolerability, and Pharmacokinetics of Orally Administered GCC4401C in Healthy Volunteers Phase 1
Terminated NCT01359618 - Determining Highest Dose Administration of TC-5214 and Evaluating Effect on the Electrical Activity in the Heart Phase 1
Completed NCT02395913 - Compare Safety and Pharmacokinetic Properties of Surfolase Capsule(Acebrophylline 100mg) and Surfolase CR(200mg) Phase 1
Completed NCT06194500 - A Study of Carbon-14-Labeled [14C]-LY3549492 in Healthy Participants Phase 1
Completed NCT05202912 - Food Effect Study of IDX-1197 in Healthy Subjects Phase 1
Completed NCT04828265 - Study of Aldafermin (NGM282) in Healthy Adult Male Japanese and Non-Japanese Subjects Phase 1